Welcome to our dedicated page for Nexgel Wt Exp 120126 SEC filings (Ticker: NXGLW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NexGel, Inc. filings document an operating company built around high-water-content hydrogel products for healthcare, consumer, diagnostic, drug-delivery and cosmetic applications. Its SEC records include current reports on material definitive agreements, asset purchase and exclusive license arrangements, contract-manufacturing-related agreements, and amendments affecting consideration and assumed obligations.
The company’s filings also cover capital-structure matters such as convertible promissory notes and private-placement financing, governance disclosures including executive appointments and employment arrangements, and Nasdaq continued-listing compliance notices. These records provide formal disclosure on NexGel’s operating agreements, securities terms, board and management changes, and public-company reporting obligations.
NexGel, Inc. has postponed its 2026 Annual Meeting of Stockholders. The meeting, originally scheduled for July 10, 2026, will now be held on July 31, 2026 at 10:00 a.m. Eastern Time. The company states this change is to allow more time to solicit proxies and obtain the requisite stockholder votes on certain proposals.
The record date for determining who is entitled to vote at the meeting remains unchanged, and all previously submitted proxies will stay valid unless revoked. The agenda and proposals are unchanged from the definitive proxy statement filed on June 9, 2026, and stockholders may still change their votes by submitting a new proxy or voting again by telephone, Internet, or in person at the rescheduled meeting.
NEXGEL, Inc. reported that Scott Henry has notified the company of his intent to resign from its Board of Directors to lighten his schedule and focus on other business ventures and personal matters. His resignation becomes effective on July 1, 2026.
Henry currently serves as Chairperson of the Board’s Audit Committee and as a member of the Compensation Committee and the Nominating and Corporate Governance Committee. The company states that his resignation is not due to any disagreement with NEXGEL or its subsidiaries regarding operations, policies, or practices.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported two open-market sales of the company’s Common Stock. He sold 6,000 shares on June 18, 2026 at a weighted average price of about $0.5921 per share, and 5,000 shares on June 23, 2026 at about $0.5933 per share. After these transactions, he directly holds 322,692 shares of NEXGEL common stock.
NexGel, Inc. filed a current report to disclose that it is using a new investor presentation as of June 17, 2026. The presentation is provided as Exhibit 99.1 and is being furnished under Regulation FD, meaning it is for information purposes and not treated as filed financial reporting.
The company states that this investor presentation will not be incorporated into other securities law filings unless specifically referenced. No new financial results, major transactions, or operational changes are described in this report itself.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported an open-market sale of common stock. On June 11, 2026, he sold 3,000 shares at $0.6136 per share. After this transaction, he continues to directly hold 333,692 shares of NEXGEL common stock.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported open-market sales of company common stock. He sold 3,000 shares at $0.5936 per share on June 4 and 3,000 shares at $0.5470 per share on June 8. After these transactions, he directly holds 336,692 shares of NEXGEL common stock, indicating he retained the vast majority of his position.
NexGel, Inc. is asking stockholders at its July 10, 2026 annual meeting to approve seven proposals, including a large potential share issuance tied to recent convertible note and warrant financings, a move from Delaware to Nevada, and significant changes to its capital structure.
Proposal 2 seeks approval under Nasdaq rules to issue more than 19.99% of currently outstanding common stock upon conversion of unsecured convertible notes and exercise of related warrants, which could result in substantial dilution if fully converted. Proposals 3–5 would reincorporate NexGel in Nevada and, either through the new Nevada charter or as Delaware fallbacks, increase authorized common stock from 25,000,000 to 100,000,000 and permit a discretionary 1‑for‑2 to 1‑for‑10 reverse stock split. As of the June 3, 2026 record date, 9,225,242 common shares were outstanding. Stockholders are also asked to elect seven directors, approve executive pay on an advisory basis, and ratify the 2026 auditor.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported selling a total of 13,000 shares of Common Stock in open-market transactions over three days. He sold 3,000 shares at $0.5975 per share, 7,000 shares at a weighted average price of $0.6058 per share, and 3,000 shares at $0.6003 per share. Following these sales, he directly holds 344,692 shares of NEXGEL Common Stock, indicating these sales represent a relatively small portion of his overall position.
NEXGEL director Henry Scott Robert acquired new derivative securities linked to the company’s common stock. He received a Convertible Promissory Note with an original principal amount of $25,000, which is convertible into up to 41,667 shares of common stock at an initial conversion price of $0.60 per share.
He also received a Warrant to Purchase Common Stock for 20,834 shares at an initial exercise price of $0.80 per share. Both the note and warrant are exercisable at his option, subject to a 4.99% beneficial-ownership limitation and other specified conditions.